Table 1.
Patient characteristics
| Age at diagnosis, years | 58 (range, 24–83) |
| Total number of included lesions | 141 |
| Gender | |
| Male | 41 (38.7) |
| Female | 65 (61.3) |
| Smoking history | |
| Never | 61 (57.5) |
| Former or current | 32 (30.2) |
| Unknown | 13 (12.3) |
| Stage at initial diagnosis | |
| IV | 106 (100) |
| Number of included lesions in a patient | |
| 1 | 87 (82) |
| 2 | 10 (9) |
| ≥3 | 9 (8) |
| Site of included metastatic lesions (total 35) | |
| Lung | 16 (46) |
| Liver | 9 (17) |
| Lymph node | 10 (29) |
| TKI drug | |
| Gefitinib (Iressa®) | 60 (57) |
| Erlotinib (Tarceva®) | 46 (43) |
| EGFR Mutation subtype | |
| Exon 19 deletion | 58 (55) |
| Exon 21 L858R | 42 (40) |
| Others | 6 (6) |
EGFR; epidermal growth factor receptor
TKI; tyrosine kinase inhibitors
Note–Unless otherwise indicated, data in parentheses are percentages